Disposal of a subsidiary - Disclosure of consideration received for disposal of a subsidiary (Details) - ACT Genomics Holdings Company Limited - USD ($) $ in Thousands	Oct. 01, 2025	Oct. 14, 2024
Disclosure of analysis of single amount of discontinued operations [line items]
Cash consideration	$ 39,873
Deferred cash consideration (Note)	6,285
Total consideration	$ 46,158	$ 46,000

The amount of consideration paid or received in respect of both obtaining and losing control of subsidiaries or other businesses. [Refer: Total for all subsidiaries [member]]

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Name IAS
-Number 7
-IssueDate 2025-01-01
-Paragraph 40
-Subparagraph a
-URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_40_a&doctype=Standard
-URIDate 2025-03-27

Name:	ifrs-full_ConsiderationPaidReceived
Namespace Prefix:	ifrs-full_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration